Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Familial Medullary Thyroid Carcinoma

Endocrine & Hormonal

Familial Medullary Thyroid Carcinoma (FMTC) Clinical Trials

Also called FMTC, RET mutation, medullary thyroid cancer

Familial medullary thyroid carcinoma (FMTC) is an autosomal dominant cancer predisposition syndrome caused by germline gain-of-function mutations in the RET proto-oncogene (chromosome 10q11.2), resulting in constitutive receptor tyrosine kinase activation. Nearly all RET mutation carriers develop medullary thyroid carcinoma (MTC) derived from parafollicular C cells by adulthood if the thyroid is not removed prophylactically.

In plain words, familial medullary thyroid carcinoma is an inherited condition where a gene change makes thyroid cancer very likely. The cancer starts in special cells of the neck's thyroid gland that make a hormone called calcitonin.

Get an email when new Familial Medullary Thyroid Carcinoma trials open or the FDA decides. Get alerts

Familial Medullary Thyroid Carcinoma

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 1 study with no phase, like observational studies.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines3

Caprelsa · Cometriq · Retevmo

Familial Medullary Thyroid Carcinoma has 3 FDA-approved medicines, 1 open or active clinical trial (1 recruiting), and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

More about Familial Medullary Thyroid Carcinoma

The treatment landscape for advanced and metastatic MTC changed dramatically with the arrival of selective RET inhibitors. Selpercatinib (Retevmo, Eli Lilly) received full FDA approval in September 2024 for advanced or metastatic RET-mutant MTC, demonstrating superior progression-free survival over older multikinase inhibitors.

Keep reading about Familial Medullary Thyroid Carcinoma

This selective agent has largely replaced the older multikinase inhibitors vandetanib (Caprelsa, approved 2011) and cabozantinib (Cometriq, Exelixis, approved 2012), which carry broader side-effect profiles due to their less targeted mechanism.

Pralsetinib (Gavreto), another selective RET inhibitor, previously held accelerated approval for RET-altered MTC but that indication was voluntarily withdrawn in 2023 when the required confirmatory trial proved infeasible.

The cancer characteristically presents with elevated serum calcitonin and carcinoembryonic antigen (CEA) that can be detected by screening before palpable disease develops. MTC can metastasize to lymph nodes, lungs, liver, and bones. Associated features in MEN 2A RET mutation carriers include pheochromocytoma (50% of MEN 2A families) and primary hyperparathyroidism (20-30% of MEN 2A families).

FMTC is primarily characterized by MTC alone, though families with certain cysteine codon RET mutations should still be screened for pheochromocytoma. Unlike sporadic MTC, hereditary MTC detected early through family screening and treated with prophylactic thyroidectomy in childhood has excellent prognosis (>95% 10-year survival if performed before calcitonin elevation).

What are the symptoms of Familial Medullary Thyroid Carcinoma?

These are common symptoms of Familial Medullary Thyroid Carcinoma, and how strong they are varies from person to person.

  • Medullary thyroid carcinoma
  • Elevated calcitonin levels
  • Thyroid nodule or mass
  • Metastatic disease with variable symptoms
  • Diarrhea from calcitonin excess
  • Associated MEN 2 features in some families

Who gets Familial Medullary Thyroid Carcinoma?

RET mutations show near-complete penetrance for medullary thyroid carcinoma by adulthood, with timing dependent on the specific codon mutation; earlier onset is common with more aggressive mutations. Affects males and females equally with no gender predominance. Autosomal dominant inheritance requires only one mutated copy from affected parent; approximately 50% of offspring inherit mutation.

Specific RET codon mutations (codons 634, 620, 611, 618, etc.) associate with varying disease severity and onset age. Genotype-phenotype correlations help predict disease aggressiveness. All populations affected; no ethnic or racial predisposition identified. Early-onset MTC common; some patients develop cancer in childhood if not screened and treated prophylactically.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Familial Medullary Thyroid Carcinoma?

There are currently 3 FDA-approved medications for Familial Medullary Thyroid Carcinoma.

vandetanib
Genzyme Corporation
Search
cabozantinib
Exelixis, Inc.
Search

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

How to get help paying for Familial Medullary Thyroid Carcinoma treatment

Charity funds and drugmaker programs for Familial Medullary Thyroid Carcinoma, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Charity funds
  • From a charity · The Assistance Fund
    Thyroid Cancer fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 16, 2026.

Every program and fund for Familial Medullary Thyroid Carcinoma, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Familial Medullary Thyroid Carcinoma

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

The RET gene page lists every condition Orphanet links to the gene and the open trials that name it.

Finding labs...

Trusted Familial Medullary Thyroid Carcinoma resources

Reputable organizations and medical references for learning more about Familial Medullary Thyroid Carcinoma, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Familial Medullary Thyroid Carcinoma

Use this Familial Medullary Thyroid Carcinoma clinical trial finder to see the 1 study recruiting patients in the United States and worldwide, with eligibility criteria in plain English. It does not test a treatment; it follows patients over time. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map, the pipeline timeline or the medication checker.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

1 active trial worldwide
Filter:
Sort:
RecruitingPatient registry covering many conditionsHasn't posted an update in over a yearNCT06523582

Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients

Sponsor: Universidad Nacional Autonoma de Mexico

Neuroendocrine neoplasms (NENs) are a heterogeneous group of lesions derived from cells with the ability to produce hormones that may arise from multiple different organs. Their clinical behavior is quite variable, encompassing both benign lesions and aggressive tumors that invad...

Ages 18 Years+3 locations
Started Aug 2022Updated 2 years agoEst. Mar 2037 (~10y 3m)
Find Familial Medullary Thyroid Carcinoma trials near you, ranked by distance →
Active trial locations1 city
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.

Trial Pipeline

Aug 2022 to Nov 2031
2023
2025
2027
2029
2031
now
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Familial Medullary Thyroid Carcinoma trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Familial Medullary Thyroid Carcinoma foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Familial Medullary Thyroid Carcinoma patient communities

Facebook groups, Reddit communities and YouTube channels where Familial Medullary Thyroid Carcinoma patients, caregivers and advocacy groups talk.

Companies developing Familial Medullary Thyroid Carcinoma treatments

Drugmakers that list Familial Medullary Thyroid Carcinoma in their rare disease portfolio, 5 in all.

Questions people ask about Familial Medullary Thyroid Carcinoma